RALEIGH, N.C.–(Business Wire)–
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that Dr.
Mark A. Sirgo, President and Chief Executive Officer, will present at the Cowen
and Company 30th Annual Health Care Conference in Boston on Wednesday, March 10
at 8:00 AM Eastern Time.
Dr. Sirgo will discuss BDSI`s product portfolio, including BEMA Buprenorphine
for pain and opioid dependence, BEMA Granisetron for nausea and vomiting, and
the commercial launch of ONSOLIS (fentanyl buccal soluble film). Dr. Sirgo will
also discuss anticipated Company milestones for 2010.
The presentation will be webcast live and can be accessed at www.bdsi.com. For
those who are not available to listen to the live broadcast, the presentation
will be archived.
About BioDelivery Sciences International
BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is
leveraging its novel and proprietary patented drug delivery technologies to
develop and commercialize, either on its own or in partnerships with third
parties, new applications of proven therapeutics. BDSI is focusing on developing
products to meet unmet patient needs in the areas of pain management and
oncology supportive care. BDSI`s pain franchise currently consists of two
products utilizing the Company`s patented BEMA buccal soluble film technology.
ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009, for
the management of breakthrough pain in patients with cancer, eighteen years of
age and older, who are already receiving and who are tolerant to opioid therapy
for their underlying persistent cancer pain. The commercial rights to ONSOLIS
are licensed to Meda AB. Our second pain product, BEMA Buprenorphine, is in
Phase 2 clinical development for the treatment of chronic pain, and in a higher
dose formulation for the treatment of opioid dependence. Additional product
candidates are being developed utilizing the BEMA technology for conditions such
as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). The Company
is also working with its patented Bioral cochleate technology to facilitate oral
dosing of drugs that would otherwise require intravenous administration. The
first product under development using the technology is Bioral Amphotericin B.
The Company`s headquarters is located in Raleigh, North Carolina. For more
information please visit www.bdsi.com.
BDSI®, BEMA® and Bioral® are registered trademarks of BioDelivery Sciences
International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals,
Inc.
Cautionary Note on Forward-Looking Statements
This press release and the statements of representatives and partners of
BioDelivery Sciences International, Inc. (the “Company”) related thereto
contain, or may contain, among other things, certain “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation, statements with
respect to the Company`s plans, objectives, projections, expectations and
intentions and other statements identified by words such as “projects,” “may,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” or similar expressions. These statements are based upon the
current beliefs and expectations of the Company`s management and are subject to
significant risks and uncertainties, including those detailed in the Company`s
filings with the Securities and Exchange Commission. Actual results may differ
significantly from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties that are
subject to change based on various factors (many of which are beyond the
Company`s control).
ICR, Inc.
Donald Ellis
925-253-1240
donald.ellis@icrinc.com
or
BioDelivery Sciences International, Inc.
Al Medwar
Vice President, Marketing and Corporate Development
919-582-9050
amedwar@bdsinternational.com
Copyright Business Wire 2010